LT - HMG-CoA reduktazės inhibitoriaus rosuvastatino derinys su fosfodiesterazės 4 inhibitoriumi, tokiu kaip roflumilastas, roflumilast-N-oksidas, skirtas panaudoti uždegiminėms plaučių ligoms gydyti
EN - Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
Legal status
Patent lapsed (non-payment of fees)
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
A61K 31/44 |
(2006.01) |
|
|
A61K 31/277 |
(2006.01) |
|
|
A61K 31/4439 |
(2006.01) |
|
|
A61K 31/437 |
(2006.01) |
|
|
A61K 31/343 |
(2006.01) |
|
|
A61K 31/502 |
(2006.01) |
|
|
A61K 31/366 |
(2006.01) |
|
|
A61K 31/22 |
(2006.01) |
|
|
A61K 31/40 |
(2006.01) |
|
|
A61K 31/405 |
(2006.01) |
|
|
A61K 31/505 |
(2006.01) |
|
|
A61K 31/352 |
(2006.01) |
|
|
A61K 31/453 |
(2006.01) |
|
|
A61P 11/00 |
(2006.01) |
|
|
A61K 45/06 |
(2006.01) |
European patent
| (11) |
Number of the document |
2359826 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
11164516.4 |
|
Date of filing the European patent application |
2007-07-03 |
| (97) |
Date of publication of the European application |
2011-08-24 |
| (45) |
Date of publication and mention of the grant of the patent |
2013-10-30
|
| (46) |
Date of publication of the claims translation |
2014-02-25
|
Priority applications
| (30) |
Number |
Date |
Country code |
|
06116625 |
2006-07-05
|
EP |
Inventors
| (72) |
Wollin, Stefan-Lutz, DE
Wohlsen, Andrea, DE
Braun, Clemens, DE
Marx, Degenhard, DE
|
Grantee
| (73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
Attorney or representative
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
Title
| (54) |
HMG-CoA reduktazės inhibitoriaus rosuvastatino derinys su fosfodiesterazės 4 inhibitoriumi, tokiu kaip roflumilastas, roflumilast-N-oksidas, skirtas panaudoti uždegiminėms plaučių ligoms gydyti |
| |
Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2019-06-19 |
13 |
289.00
EUR
|
Legal status
|
Patent lapsed (non-payment of fees)
|
|
|
Invalidation date |
2020-07-03 |
